Shots:
- argenx has entered into a definitive agreement to acquire Forte Biosciences, strengthening argenx’s innovative immunology portfolio with FB102
- As per the deal, argenx will acquire Forte Biosciences for $77/share in cash, representing a total equity value of ~$2.2B; closing is expected in Q3’26
- FB102 is an anti-CD122 antibody showing clinical PoC in vitiligo & celiac disease, with potential across autoimmune diseases. Positive P-Ib data were reported in both indications, while P-II celiac data are expected in H2’26
Ref: Businesswire | Image: Forte Biosciences | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
